dc.contributor.author | Kerrison, WGJ | |
dc.contributor.author | Thway, K | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Huang, PH | |
dc.coverage.spatial | Netherlands | |
dc.date.accessioned | 2023-05-30T12:59:39Z | |
dc.date.available | 2023-05-30T12:59:39Z | |
dc.date.issued | 2023-04-01 | |
dc.identifier | 103955 | |
dc.identifier | S1040-8428(23)00043-4 | |
dc.identifier.citation | Critical Reviews in Oncology Hematology, 2023, 184 pp. 103955 - | |
dc.identifier.issn | 1040-8428 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5819 | |
dc.identifier.eissn | 1879-0461 | |
dc.identifier.eissn | 1879-0461 | |
dc.identifier.doi | 10.1016/j.critrevonc.2023.103955 | |
dc.description.abstract | Leiomyosarcoma (LMS) is a soft tissue sarcoma of smooth muscle origin that can arise in multiple anatomical sites and is broadly classified as extra-uterine LMS or uterine LMS. There is substantial interpatient heterogeneity within this histological subtype, and despite multi-modal therapy, clinical management remains challenging with poor patient prognosis and few new therapies available. Here we discuss the current treatment landscape of LMS in both the localised and advanced disease setting. We further describe the latest advances in our evolving understanding of the genetics and biology of this group of heterogeneous diseases and summarise the key studies delineating the mechanisms of acquired and intrinsic chemotherapy resistance in this histological subtype. We conclude by providing a perspective on how novel targeted agents such as PARP inhibitors may usher in a new paradigm of biomarker-driven therapies that will ultimately impact the outcomes of patients with LMS. | |
dc.format | Print-Electronic | |
dc.format.extent | 103955 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE INC | |
dc.relation.ispartof | Critical Reviews in Oncology Hematology | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Doxorubicin | |
dc.subject | Genomics | |
dc.subject | Leiomyosarcoma | |
dc.subject | PARP inhibitors | |
dc.subject | Soft tissue sarcomas | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Leiomyosarcoma | |
dc.subject | Sarcoma | |
dc.subject | Antineoplastic Agents | |
dc.subject | Uterine Neoplasms | |
dc.subject | Biology | |
dc.title | The biology and treatment of leiomyosarcomas. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-03-04 | |
dc.date.updated | 2023-05-30T12:59:12Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.critrevonc.2023.103955 | |
rioxxterms.licenseref.startdate | 2023-04-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36893945 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.critrevonc.2023.103955 | |
pubs.volume | 184 | |
icr.researchteam | Mol and Systems Oncology | |
dc.contributor.icrauthor | Huang, Paul | |
icr.provenance | Deposited by Mr Arek Surman on 2023-05-30. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S1040842823000434-main.pdf | |